Pannaree PiromkraipakTipparat ParakawSuttinee PhuagkhaopongSirada SrihirunSukumal ChongthammakunKulathida ChaithirayanonPornpun VivithanapornMahidol University2019-08-232019-08-232018-01-01Canadian Journal of Physiology and Pharmacology. Vol.96, No.8 (2018), 798-80612057541000842122-s2.0-85050941403https://repository.li.mahidol.ac.th/handle/20.500.14594/45277© 2018, Canadian Science Publishing. All rights reserved. Glioblastoma is the most aggressive type of brain cancer with the highest proliferation, invasion, and migration. Montelukast and zafirlukast, 2 widely used leukotriene receptor antagonists (LTRAs) for asthma treatment, inhibited invasion and migration of glioblastoma cell lines. Montelukast induces apoptosis and inhibits cell proliferation of various cancer cells. Herein, apoptotic and antiproliferative effects of montelukast and zafirlukast were investigated in 2 glioblastoma cell lines, A172 and U-87 MG. Both LTRAs induced apoptosis and inhibited cell proliferation of glioblastoma cells in a concentration-dependent manner. Montelukast was more cytotoxic and induced higher levels of apoptosis than zafirlukast in A172 cells, but not in U-87 MG cells. Both drugs decreased expression of B-cell lymphoma 2 (Bcl-2) protein without affecting Bcl-2-associated X (Bax) levels. LTRAs also reduced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2). In contrast, zafirlukast showed a greater antiproliferative effect than montelukast and induced G0/G1 cell cycle arrest by upregulating p53 and p21 expression. These results suggested the therapeutic potential of LTRAs in glioblastoma.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1139/cjpp-2017-0757